No association of CNR1 gene variations with susceptibility to schizophrenia

Neuroscience Letters

Volumn 426, Issue 1, 2007, Pages 29-33

  Seifert, Jürgen ^a   Ossege, Sebastian ^a,b   Emrich, Hinderk M ^a   Schneider, Udo ^a,b   Stuhrmann, Manfred ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Psychiatry and Psychotherapy   (Germany)

Author keywords

Cannabinoid receptor; CNR1 gene; Schizophrenia

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CNR1 GENE; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHIATRY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ALLELES; ASSOCIATION; BASE SEQUENCE; BRAIN; BRAIN CHEMISTRY; DNA MUTATIONAL ANALYSIS; ENDOCANNABINOIDS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 34548855044     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.08.008     Document Type: Article

References (24)

1. Ballmaier M., Bortolato M., Rizzetti C., Zoli M., Gessa G., Heinz A., and Spano P. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32 (2007) 2098-2107
2. Ballon N., Leroy S., Roy C., Bourdel M.C., Charles-Nicolas A., Krebs M.O., and Poirier M.F. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J. 6 (2006) 126-130
3. Cao Q., Martinez M., Zhang J., Sanders A.R., Badner J.A., Cravchik A., Markey C.J., Beshah E., Guroff J.J., Maxwell M.E., Kazuba D.M., Whiten R., Goldin L.R., Gershon E.S., and Gejman P.V. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 43 (1997) 1-8
4. Comings D.E., Muhleman D., Gade R., Johnson P., Verde R., Saucier G., and MacMurray J. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol. Psychiatry 2 (1997) 161-168
5. Craddock N., O'Donovan M.C., and Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 32 (2006) 9-16
6. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., and Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57 (2005) 594-608
7. Fritzsche M. Are cannabinoid receptor knockout mice animal models for schizophrenia?. Med. Hypotheses 56 (2001) 638-643
8. Gadzicki D., Muller-Vahl K., and Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol. Cell Probes 13 (1999) 321-323
9. Gray J.A., Joseph M.H., Hemsley D.R., Young A.M., Warburton E.C., Boulenguez P., Grigoryan G.A., Peters S.L., Rawlins J.N., Taib C.T., Yee B.K., Cassaday H., Weiner I., Gal G., Gusak O., Joel D., Shadach E., Shalev U., Tarrasch R., and Feldon J. The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: implications for schizophrenia. Behav. Brain Res. 71 (1995) 19-31
10. Hall W. Is cannabis use psychotogenic?. Lancet 367 (2006) 193-195
11. Haller J., Szirmai M., Varga B., Ledent C., and Freund T.F. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav. Pharmacol 16 (2005) 415-422
12. Hermann A., Kaczocha M., and Deutsch D.G. 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. AAPS J. 8 (2006) E409-E412
13. Hoehe M.R., Caenazzo L., Martinez M.M., Hsieh W.T., Modi W.S., Gershon E.S., and Bonner T.I. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol. 3 (1991) 880-885
14. Leroy S., Griffon N., Bourdel M.C., Olie J.P., Poirier M.F., and Krebs M.O. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet. 105 (2001) 749-752
15. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., and Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10 (1999) 1665-1669
16. Madsen M.V., Peacock L., Werge T., and Andersen M.B. Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. J Psychopharmacol. 20 (2006) 622-628
17. Martinez-Gras I., Hoenicka J., Ponce G., Rodriguez-Jimenez R., Jimenez-Arriero M.A., Perez-Hernandez E., Ampuero I., Ramos-Atance J.A., Palomo T., and Rubio G. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur. Arch Psychiatry Clin. Neurosci. 256 (2006) 437-441
18. Morita Y., Ujike H., Tanaka Y., Uchida N., Nomura A., Ohtani K., Kishimoto M., Morio A., Imamura T., Sakai A., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., and Kuroda S. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci. Lett. 376 (2005) 182-187
19. Ortega-Gutierrez S., Hawkins E.G., Viso A., Lopez-Rodriguez M.L., and Cravatt B.F. Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry 43 (2004) 8184-8190
20. Schneider U., Leweke F.M., Mueller-Vahl K.R., and Emrich H.M. Cannabinoid/anandamide system and schizophrenia: is there evidence for association?. Pharmacopsychiatry 31 Suppl. 2 (1998) 110-113
21. Tsai S.J., Wang Y.C., and Hong C.J. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr. Genet. 10 (2000) 149-151
22. Ujike H., and Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J. Pharmacol. Sci. 96 (2004) 376-381
23. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., Fujiwara Y., Sakai A., and Kuroda S. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 7 (2002) 515-518
24. Zuo L., Kranzler H.R., Luo X., Covault J., and Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol. Psychiatry 62 (2007) 616-626